Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2024
Reporting Period: Quarterly period ended March 31, 2024
This filing serves as a notification that the company issued a press release and an earnings presentation regarding its financial results for the first quarter of 2024. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) rather than the body of this 8-K.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release and earnings presentation but are not disclosed within the 8-K summary text itself.
Material Changes
No material changes or comparative financial data versus the prior period are detailed in this filing text. Investors must refer to the attached exhibits for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Management Commentary: The company released an earnings presentation (Exhibit 99.2) which typically contains management commentary, outlook, and guidance, though the specific content is not summarized in this document.
Risks and Contingencies: No specific risks or contingencies are listed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2024 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Earnings Presentation) for updated clinical trial timelines, product launch status, and forward-looking guidance.
- Verify the company's cash runway and burn rate as disclosed in the full financial statements referenced in the exhibits.
- Confirm any updates to the development pipeline for the company's core assets (e.g., Dayvigo, Dayvigo XR) mentioned in the presentation.